拉夫米定联合苷必妥治疗慢性乙型肝炎病人的近期疗效

研究拉米夫定联合苷必妥治疗慢性乙型肝炎病人的近期疗效和安全性。选择16例慢性乙型肝炎患者用拉米夫定（100mg/d)和苷必妥(1mg/d）治疗为观察组,选择15例患者单独服用拉米夫定（100mg/d)作对照,共治疗12周。疗效评估包括肝功能和HBV复制指标。治疗12周疗程结束时,血清HBVDNA阴转率在两组间差异无显著性（100％对80．0％,P＞0．05）,观察组HBeAg阴转率显著高于对照组（87．5％对26．7％,P＜0．01）,HBeAg血清转换率在两组间差异有显著性（78．6％对25．09％,P＜0．05）,观察组ALT的复常率显著高于对照组（100．0％对66．7％,P＜0．05）。未发生不良反应。拉米夫定联合苷必妥治疗慢性乙型肝炎的近期疗效肯定, 安全性好。

Short-term effect of Lamivudine with Gan Bi Tuo treatment in patients with hepatits B

To evaluate the short-term effect and safety of Lamivudine with GanBiTuo (Transfer Factor against Hepatitis B)treatment in chronic hepatitis B patients.31 patients with chronic hepatitis B enrolled were randomized into observed goup (16 cares),which were administered Lamivudine 100mg and GanBiTuo.1mg daily for 12 weeks,and control group (15cares),which were adnimisteral Lamivudine 100mg daily for 12 weeks.The liver function and HBV markers were examined.There were no significant difference between the HBVDNA response rate of two groups (100% VS 80.0%,P>0.05).HBeAg response rate in obrerved group was higher than in control group (87.5% VS 26.7%,P<0.01).Proportion of HBeAg/anti-HBe seroconversion had difference between two groups (78.6% VS 25.0%,P<0.05).ALT normalization rate in observed grop was higher than in control group (100% vs 66.7%, P<0.05).There was few drug-related adverse event.HBV replication could be inhibited by short-term treatment with Lamivudine/GanBiTuo accompanied with good efficacy and safety.